Table 1.
Clinical characteristics of the study population
| Parameter | Unit | Diabetes mellitus | Control | p value |
|---|---|---|---|---|
| n | 25 | 25 | ||
| CAD | [n] | 25 | 25 | |
| Age | [years] | 65 ± 1.4 | 66 ±1.6 | n.s. |
| Male sex | [n] | 15 | 21 | n.s. |
| Body mass index | [kg/m2] | 29.7 ± 1.0 | 26.6 ±0.7 | p≤0.05 |
| Systolic blood pressure | [mmHg] | 151 ±5 | 142 ±3 | n.s. |
| Diastolic blood pressure | [mmHg] | 87 ±2 | 86 ±2 | n.s. |
| Mean arterial pressure | [mmHg] | 108 ±3 | 105 ±2 | n.s. |
| Triglycerides | [mg/dL] | 142 ± 12 | 133 ±9 | n.s. |
| Total cholesterol | [mg/dL] | 174 ±9 | 182 ±9 | n.s. |
| LDL cholesterol | [mg/dL] | 107 ±8 | 111 ±7 | n.s. |
| HDL cholesterol | [mg/dL] | 51 ±2 | 52 ±3 | n.s. |
| Plasma glucose | [mg/dL] | 148 ±8 | 105 ±8 | p≤0.001 |
| HbA1c | [%] | 7.0 ±0.2 | 5.8 ±0.2 | p≤0.001 |
| ASS | [%] | 88 | 100 | n.s. |
| Clopidogrel | [%] | 20 | 68 | p≤0.001 |
| Beta blocker | [%] | 80 | 84 | n.s. |
| ACE-I or ARB | [%] | 92 | 84 | n.s. |
| Statin | [%] | 84 | 96 | n.s. |
| Oral antidiabetics | [%] | 60 | 0 | p≤0.001 |
| Insulin | [%] | 44 | 0 | p≤0.001 |
CAD: coronary artery disease; LDL cholesterol: low density lipoprotein cholesterol; HDL cholesterol: high density lipoprotein cholesterol; ACE-I: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker.